These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25721064)

  • 1. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor.
    Papadopoulos KP; Isaacs R; Bilic S; Kentsch K; Huet HA; Hofmann M; Rasco D; Kundamal N; Tang Z; Cooksey J; Mahipal A
    Cancer Chemother Pharmacol; 2015 May; 75(5):887-95. PubMed ID: 25721064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
    Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA
    MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
    Herbst RS; Eckhardt SG; Kurzrock R; Ebbinghaus S; O'Dwyer PJ; Gordon MS; Novotny W; Goldwasser MA; Tohnya TM; Lum BL; Ashkenazi A; Jubb AM; Mendelson DS
    J Clin Oncol; 2010 Jun; 28(17):2839-46. PubMed ID: 20458040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
    Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Mice With Humanized Livers Demonstrate Human-Specific Hepatotoxicity Caused by a Therapeutic Antibody Against TRAIL-Receptor 2/Death Receptor 5.
    Nihira K; Nan-Ya KI; Kakuni M; Ono Y; Yoshikawa Y; Ota T; Hiura M; Yoshinari K
    Toxicol Sci; 2019 Jan; 167(1):190-201. PubMed ID: 30202993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tetravalent anti-DR5 antibody without cross-linking direct induces apoptosis of cancer cells.
    Liu F; Si Y; Liu G; Li S; Zhang J; Ma Y
    Biomed Pharmacother; 2015 Mar; 70():41-5. PubMed ID: 25776477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
    Leong S; Cohen RB; Gustafson DL; Langer CJ; Camidge DR; Padavic K; Gore L; Smith M; Chow LQ; von Mehren M; O'Bryant C; Hariharan S; Diab S; Fox NL; Miceli R; Eckhardt SG
    J Clin Oncol; 2009 Sep; 27(26):4413-21. PubMed ID: 19652058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma.
    Kawahara T; Toso C; Yamaguchi K; Cader S; Douglas DN; Nourbakhsh M; Lewis JT; Churchill TA; Yagita H; Kneteman NM
    Liver Int; 2013 Oct; 33(9):1441-8. PubMed ID: 23895107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells.
    Liu J; Edagawa M; Goshima H; Inoue M; Yagita H; Liu Z; Kitajima S
    Biochem Biophys Res Commun; 2014 Mar; 445(2):320-6. PubMed ID: 24530917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I study of MEDI-575, a PDGFRα monoclonal antibody, in Japanese patients with advanced solid tumors.
    Murakami H; Ikeda M; Okusaka T; Inaba Y; Iguchi H; Yagawa K; Yamamoto N
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):631-9. PubMed ID: 26223436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
    Camidge DR; Herbst RS; Gordon MS; Eckhardt SG; Kurzrock R; Durbin B; Ing J; Tohnya TM; Sager J; Ashkenazi A; Bray G; Mendelson D
    Clin Cancer Res; 2010 Feb; 16(4):1256-63. PubMed ID: 20145186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors.
    Haynes NM; Hawkins ED; Li M; McLaughlin NM; Hämmerling GJ; Schwendener R; Winoto A; Wensky A; Yagita H; Takeda K; Kershaw MH; Darcy PK; Smyth MJ
    J Immunol; 2010 Jul; 185(1):532-41. PubMed ID: 20505139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.
    Tolcher AW; Mita M; Meropol NJ; von Mehren M; Patnaik A; Padavic K; Hill M; Mays T; McCoy T; Fox NL; Halpern W; Corey A; Cohen RB
    J Clin Oncol; 2007 Apr; 25(11):1390-5. PubMed ID: 17416859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).
    Forero-Torres A; Shah J; Wood T; Posey J; Carlisle R; Copigneaux C; Luo FR; Wojtowicz-Praga S; Percent I; Saleh M
    Cancer Biother Radiopharm; 2010 Feb; 25(1):13-9. PubMed ID: 20187792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
    Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity.
    Higuchi H; Bronk SF; Taniai M; Canbay A; Gores GJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):461-7. PubMed ID: 12388624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.
    Mau-Sørensen M; Dittrich C; Dienstmann R; Lassen U; Büchler W; Martinius H; Tabernero J
    Cancer Chemother Pharmacol; 2015 May; 75(5):1065-73. PubMed ID: 25814216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of toxicity and single-dose pharmacokinetics of intravenous ursolic acid liposomes in healthy adult volunteers and patients with advanced solid tumors.
    Wang XH; Zhou SY; Qian ZZ; Zhang HL; Qiu LH; Song Z; Zhao J; Wang P; Hao XS; Wang HQ
    Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):117-25. PubMed ID: 23134084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
    Cretney E; Takeda K; Smyth MJ
    Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.